Article
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
British journal of cancer - 21 Oct 2008
Kweekel D M, Koopman M, Antonini N F, Van der Straaten T, Nortier J W R, Gelderblom H, Punt C J A, Guchelaar H-J
Abstract excerpt
A Valine residue at position 105 of the GSTP1 protein results in decreased enzyme activity. As nuclear GSTP1 activity decreases irinotecan cytotoxicity, Val-allele carriers may benefit more from irinotecan chemotherapy. Our aim was to investigate the association of GSTP1 genotype with treatment outcome of irinotecan. Progression-free survival (PFS) and toxicity were determined in 267 metastatic colorectal cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.